Last reviewed · How we verify
ACYC vehicle — Competitive Intelligence Brief
phase 3
Antiviral agent (topical formulation)
Viral DNA polymerase (via acyclovir active ingredient)
Virology/Dermatology
Small molecule
Live · refreshed every 30 min
Target snapshot
ACYC vehicle (ACYC vehicle) — Bausch Health Americas, Inc.. ACYC vehicle is a topical formulation designed to enhance the delivery and efficacy of acyclovir for localized antiviral treatment.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ACYC vehicle TARGET | ACYC vehicle | Bausch Health Americas, Inc. | phase 3 | Antiviral agent (topical formulation) | Viral DNA polymerase (via acyclovir active ingredient) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antiviral agent (topical formulation) class)
- Bausch Health Americas, Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ACYC vehicle CI watch — RSS
- ACYC vehicle CI watch — Atom
- ACYC vehicle CI watch — JSON
- ACYC vehicle alone — RSS
- Whole Antiviral agent (topical formulation) class — RSS
Cite this brief
Drug Landscape (2026). ACYC vehicle — Competitive Intelligence Brief. https://druglandscape.com/ci/acyc-vehicle. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing